- Home
- BTAI vs DTIL Comparison
BTAI vs DTIL Comparison
Compare BTAI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- DTIL
- Stock Information
- Founded
- BTAI 2017
- DTIL 2006
- Country
- BTAI United States
- DTIL United States
- Employees
- BTAI N/A
- DTIL N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- DTIL Health Care
- Exchange
- BTAI Nasdaq
- DTIL Nasdaq
- Market Cap
- BTAI 52.7M
- DTIL 55.3M
- IPO Year
- BTAI 2018
- DTIL 2019
- Fundamental
- Price
- BTAI $2.66
- DTIL $5.71
- Analyst Decision
- BTAI Buy
- DTIL Strong Buy
- Analyst Count
- BTAI 5
- DTIL 2
- Target Price
- BTAI $32.80
- DTIL $47.00
- AVG Volume (30 Days)
- BTAI 1.5M
- DTIL 97.4K
- Earning Date
- BTAI 11-13-2025
- DTIL 11-03-2025
- Dividend Yield
- BTAI N/A
- DTIL N/A
- EPS Growth
- BTAI N/A
- DTIL N/A
- EPS
- BTAI N/A
- DTIL N/A
- Revenue
- BTAI $868,000.00
- DTIL $1,261,000.00
- Revenue This Year
- BTAI N/A
- DTIL N/A
- Revenue Next Year
- BTAI $614.78
- DTIL $135.19
- P/E Ratio
- BTAI N/A
- DTIL N/A
- Revenue Growth
- BTAI N/A
- DTIL N/A
- 52 Week Low
- BTAI $1.17
- DTIL $3.61
- 52 Week High
- BTAI $13.28
- DTIL $9.39
- Technical
- Relative Strength Index (RSI)
- BTAI 38.51
- DTIL 67.49
- Support Level
- BTAI $2.42
- DTIL $5.26
- Resistance Level
- BTAI $2.70
- DTIL $5.80
- Average True Range (ATR)
- BTAI 0.19
- DTIL 0.19
- MACD
- BTAI 0.00
- DTIL 0.07
- Stochastic Oscillator
- BTAI 12.17
- DTIL 90.91
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.